Search Results - anti-cancer

11 Results

Sort By:

A method to induce ferroptosis and to downregulate androgen receptor/androgen receptor splice variant in prostate cancer cells

Prostate cancer (PCa) effects approximately three million men in the United States every year. About 10-20% of the cases of prostate cancer are castrate-resistant prostate cancer (CRPC). This form of PCa is highly resistant to what Is known as androgen depletion therapy and is often fatal. All types of PCa are sensitive to androgen receptor signaling...

Published: 10/26/2023 | Inventor(s): Zhihui Qin, Liping Xu

Keywords(s): Anti-cancer, Cancer, Cancer Therapies, Drug Delivery, Drug Target, Prostate Cancer

Category(s): Medical, Diseases, Drug Discovery, Pharmaceuticals, Oncology

Fc-folate conjugate for the treatment of triple negative breast cancer

Approximately 13% of women in the United States will develop breast cancer according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...

Published: 12/7/2022 | Inventor(s): Cecilia Speyer

Keywords(s): Anti-cancer, Breast Cancer, Cancer, Cancer Therapies

Category(s): Antibodies, Assays, Biology, Biomedical, Chemical Processing/Synthesis, Diseases, Drug Delivery, Life Science, Oncology, Protein/peptides, Receptors/targets, Small molecule, Therapeutics

Anti-Cancer Activity of a 2,5-Substituted Pyrimidine

This technology is a novel class of compounds that induce apoptosis in cancerous cells. BackgroundARR molecules (adamantyl-substituted retinoid-related) are a unique class of compounds which have been found to induce apoptosis, or cell death, in a large number of tumor types. SHP plays a role in cellular proliferation. Molecules that Interfere with...

Published: 12/7/2022 | Inventor(s): Joseph Fontana, Ramzi Mohammad, Lulu Farhana, Amro Aboukameel, Marcia Dawson, Zebin Xia

Keywords(s): Analog or Analogue, Anti-cancer

Category(s): Life Science, Oncology, Therapeutics, Diseases

SH80 Combinations

BackgroundSH35/SH80 evolved from an effort to improve upon the anti-tumor activity of XK469. XK469 is a compound, currently in Phase 1 clinical trials. The clinical trials include patients with bladder, breast, colorectal, esophageal, head and neck, kidney, liver, lung, mesothelioma, pancreas and sarcoma cancers. Moving a chlorine atom from one position...

Published: 3/2/2022 | Inventor(s): Lisa Polin

Keywords(s): Anti-cancer, Compound

Category(s): Life Science, Oncology, Therapeutics

Activated T Cells and Activated T Cells Armed with BiSpecific Antibodies Directed at Cancer Antigens are Poor Responders to Alloantigens May Help Engraftment and Improve Anti-Tumor Effects

BackgroundThe treatment of hematologic malignancies with allogeneic stem cell transplant is limited by the numbers of allogeneic donors. Umbilical cord blood stem transplants have been an important alternative source of hematopoietic stem cells. However, failure or delayed engraftment remains the critical barrier to the success of the transplants....

Published: 3/2/2022 | Inventor(s): Lawrence Lum

Keywords(s): Anti-cancer

Category(s): Life Science, Therapeutics, Diseases, Infectious disease

Para-Amino Substituent on the D Ring of Green Tea Polyphenol Epigallocatechin-3-Gallate as Novel Proteasome Inhibitor and Cancer Apoptosis Inducer

This technology is a group of (-)EGCG analogs with stable and improved anti-tumor activities. Background & Unmet Need:Catechins are a type of plant-derived antioxidant whose biological activities may play an effect on cancer prevention. Green tea has long been lauded to have ingredients that protect cells from the DNA damage that causes cancer....

Published: 2/28/2022 | Inventor(s): Qingping Dou, Kristin Landis-Piwowar, Tak-Hang Chan, Kumi Osanai

Keywords(s): Anti-cancer, Breast Cancer, Compound, Prostate Cancer

Category(s): Life Science, Oncology, Therapeutics, Diseases

Translation Regulated (TR)-Mediated Gene Expression: Novel Expression and Reporter Vectors

Background: Often referred to as the crucial "drug discovery tool", cell based technology is one of the most significant sectors of pharmaceutical research and development. Of particular importance has been the development of information-rich cellular assays that determine drug candidate efficacy and safety (target identification, validation...

Published: 4/17/2022 | Inventor(s): Leon Carlock, Maria Cypher

Keywords(s): Animal Model, Anti-cancer, Cancer, Cancer risk, Cancer Therapies, Diagnostics, Imaging, Therapeutics

Category(s): Life Science, Diagnostics, Research tools, Assays, Cell lines, Oncology

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 12/6/2022 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other

Repurposing AKT Inhibitors for the Treatment of Protein Misfolding and Protein Trafficking Diseases

WSU researchers have generated a reagent to understand the degenerative processes occurring in Pelizaeus‑Merzbacher disease (PMD) and to study the intracellular signaling that occurs because of these diseased processes. They have deduced that the use of AKT inhibitors may reduce disease severity in patients with a wide range of degenerative diseases. Background...

Published: 2/8/2022 | Inventor(s): Alexander Gow, Cherie Southwood

Keywords(s): Alzheimer's Disease, Anti-cancer, Neuro-disorders, Parkinson's

Category(s): Life Science, Neurological disorders, Therapeutics, Diseases

Hox B4

This invention is a novel therapy for cancer using Hox B4 to induce apoptosis in leukemia cell lines. Background & Unmet Need: B‑cell chronic lymphocytic leukemia is the most common type of leukemia in adults. The B cells grow uncontrollably and invade the bone marrow and blood where they crowd out the healthy cells. There is a need to...

Published: 10/5/2018 | Inventor(s): Kamal Mubarak, Ramzi Mohammad, Robert Pauley, Larry Tait

Keywords(s): Anti-cancer, Gene, Protein

Category(s): Therapeutics, Life Science, Oncology, Diseases

1 2